NCT06002711 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Cao M, Ding W, Han X, Suo S, Sun Y, Wang Y, Qu J, Zhang X, Zhou Y
Brain T1rho mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study. J Neurooncol. 2019 Jan;141(1):245-252. doi: 10.1007/s11060-018-03033-7. Epub 2018 Nov 9.
Cao M, Suo S, Zhang X, Wang X, Xu J, Yang W, Zhou Y
Qualitative and Quantitative MRI Analysis in IDH1 Genotype Prediction of Lower-Grade Gliomas: A Machine Learning Approach. Biomed Res Int. 2021 Jan 22;2021:1235314. doi: 10.1155/2021/1235314. eCollection 2021.
Cao M, Wang X, Liu F, Xue K, Dai Y, Zhou Y
A three-component multi-b-value diffusion-weighted imaging might be a useful biomarker for detecting microstructural features in gliomas with differences in malignancy and IDH-1 mutation status. Eur Radiol. 2023 Apr;33(4):2871-2880. doi: 10.1007/s00330-022-09212-5. Epub 2022 Nov 8.
Dextraze K, Saha A, Kim D, Narang S, Lehrer M, Rao A, Narang S, Rao D, Ahmed S, Madhugiri V, Fuller CD, Kim MM, Krishnan S, Rao G, Rao A
Spatial habitats from multiparametric MR imaging are associated with signaling pathway activities and survival in glioblastoma. Oncotarget. 2017 Dec 5;8(68):112992-113001. doi: 10.18632/oncotarget.22947. eCollection 2017 Dec 22.
Park JE, Kim HS, Kim N, Park SY, Kim YH, Kim JH
Spatiotemporal Heterogeneity in Multiparametric Physiologic MRI Is Associated with Patient Outcomes in IDH-Wildtype Glioblastoma. Clin Cancer Res. 2021 Jan 1;27(1):237-245. doi: 10.1158/1078-0432.CCR-20-2156. Epub 2020 Oct 7.

Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study

Clinical trial NCT06002711 - References